Halo's lead program, H1614, is a small-molecule first-in-class inhibitor of HA synthesis. Our development program for H1614 focuses on a proprietary reformulation of 4-methylumbelliferone with plans for a Phase 2 trial in patients with Group 3 pulmonary hypertension.

These plans are supported by significant research and development efforts from our team, including the results of a Phase 1 study and a Phase 2a proof of concept clinical trial, both completed at Stanford University. The results of the Phase 2a study are to be released at the 2024 American Thoracic Society (ATS) Meeting in May.

Phase 1

https://clinicaltrials.gov/study/NCT02780752

Phase 2a

https://clinicaltrials.gov/study/NCT05128929

The Foundation

Targeting Hyaluronan (HA) is a novel, differentiated mechanism with potential to transform disease states

Our Science

The People

The Foundation

Halo's extended team includes leaders in the fields of pulmonary medicine and drug development. We are closely connected to Stanford University's unparalleled ecosystem of drug discovery.

Our Team

Learn More

The Foundation

Learn More

Learn more about Halo, our pipeline, and our work in pulmonary hypertension and interstitial lung diseases